- Disease: Acute SARS-CoV-2
- Study type: Observational Cohort Study
- Study type descriptors: Retrospective, Single centre
- Study aim: To determine the efficacy and safety of a combination of two antivirals, with and without a monoclonal antibody, in both the early and later phases of SARS-CoV-2 infection in immunocompromised patients
- Number of participants enrolled: 11
- Study enrolling from to
- Study includes follow-up for 3 months
Study Data
- Adults
- Elderly
- Fragile population
- Immunocompromised host
- Hospital wide
- Infectious diseases unit
- SARS-CoV-2
- Acute SARS-CoV-2
- Pharmacological intervention
- Antivirals
- Remdesivir
- Monoclonal antibodies
- Nirmatrelvir/Ritonavir
- Sotrovimab
External Links
Other information
Funders:
- NextGenerationE UMUR PNRR Extended Partnership initiative on Emerging Infectious Diseases
- POR Campania
If you would like to contact the Principal Investigator of the study please email: ccb@ateneo.univr.it
The data is updated up to